• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    4/30/24 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email

    The Company is proud to collaborate on a number of additional initiatives during the month of May

    Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time.

    "Skin cancer is the most common cancer in the United States, with more annual diagnoses than all other cancers combined, but it is also one of the most preventable, by practicing sun safety and limiting exposure to UV rays,"1,2 said Derek Maetzold, president and chief executive officer of Castle Biosciences. "As a long-time Friendswood resident, both personally and professionally, and as a steadfast advocate and board member of IMPACT Melanoma, I cannot think of a better way to honor Skin Cancer Awareness Month than by partnering with this great organization to showcase our joint commitment to sun safety and skin cancer prevention."

    The City of Friendswood's Sun Safe Leadership initiative encompasses multiple IMPACT programs being implemented throughout the community, including the installation of sunscreen dispensers for access to free sunscreen and portable shade tents in city parks, prevention education for families, and ultraviolet protection factor (UPF) protective clothing for outdoor workers, including Parks & Recreation and city employees.

    "As a Partner in Prevention with IMPACT Melanoma, Castle Biosciences is helping to raise awareness of the importance of being sun safe year-round to help prevent future skin cancer diagnoses," said Deb Girard, Executive Director at IMPACT Melanoma. "We are grateful for Castle's continued support, equipping families and communities with the knowledge and resources to truly embrace sun safety practices."

    Friendswood Mayor and former NASA astronaut, Mike Foreman, will open the ribbon cutting with brief remarks followed by an award presentation for the city of Friendswood. "May is Skin Cancer Awareness Month, a time to educate people about the dangers of skin cancer, share information and help save lives. That is why the City of Friendswood is proud to partner with IMPACT Melanoma and Castle Biosciences to designate Friendswood as a Sun Safe Leadership Model City," said Foreman. "We look forward to spreading awareness and information to our residents, families and friends, and protecting those we care about."

    Local melanoma survivor, Anne Ramsey, will also take part in the celebration to share her melanoma journey. "I am honored to join the City of Friendswood, IMPACT Melanoma and Castle Biosciences to help inaugurate the Sun Safe City program in Texas. I hope that by sharing my story, I can inspire others to prioritize skin cancer prevention and make regular skin checks part of their normal health regimens."

    Additional initiatives Castle is supporting during Skin Cancer Awareness Month:

    The Skin Cancer Foundation

    The Champions for Change Gala is The Skin Cancer Foundation's signature fundraising event, being held on May 15 in New York City. Proceeds from this event, in which Castle is a sponsor for the third consecutive year, will support the Foundation's lifesaving educational campaigns, community programs and research initiatives.

    The Sun Bus

    As a platinum sponsor, Castle is proud to support The Sun Bus for the fourth consecutive year. Kicking off May events, The Sun Bus will spend several days at NASCAR in Kansas City before heading west for five additional stops throughout Colorado. Launched by the Colorado Melanoma Foundation in 2019, The Sun Bus is a mobile clinic and classroom that provides free skin screenings, skin cancer awareness and sun safety education to residents across several southwestern states in the United States.

    The Sun Bus launched its 2024 tour in February and plans to make more than 40 stops during its 10-state tour, including several days at NASCAR events in Kansas City and Phoenix, before wrapping up in November. See the 2024 Sun Bus itinerary here.

    AIM at Melanoma

    Castle is a proud industry sponsor for AIM at Melanoma, whose goal is to end melanoma in our lifetime while improving the lives of those it affects. Castle is a national sponsor of their 2024 Steps Against Melanoma Walks throughout May, including those in Alabama, Pennsylvania, California and Texas. Melanoma survivor Ramsey is the chair for the Houston walk, happening June 8. Visit the AIM at Melanoma website for additional information about upcoming walks.

    The Melanoma Research Foundation (MRF)

    Castle is also collaborating with the MRF on key educational and fundraising events taking place during the month of May and beyond, including, for the fourth consecutive year, the MRF Miles for Melanoma 5K run/walks. Castle is sponsoring the Boston and Washington, D.C., walks in May, as well as several others throughout the year. Visit the Miles for Melanoma website for information.

    Additionally, Castle is participating in the MRF Patient Symposia Educational Series, including three patient and caregiver symposia in May. More information can be found here.

    The Balancing Act® Airing on Lifetime TV®

    Also in May, Castle is collaborating with The Balancing Act airing on Lifetime TV, to spread the word about the risks and impacts of skin cancer. In the segment, hosts Olga Villaverde and Montel Williams will interview Dr. David Cotter, M.D., Ph.D., dermatologist at Las Vegas Dermatology, to discuss skin cancer prevention, risk factors and emerging technologies, including Castle's DecisionDx®-Melanoma and DecisionDx®-SCC tests that identify a patient's risk of recurrence and metastasis. Julie Bain, skin cancer survivor and the senior director of science and education at The Skin Cancer Foundation, will also share her skin cancer journey. The segment will air twice: on May 6 and May 14, both at 7:30 a.m. Eastern time and Pacific time, and will be available on demand on the Balancing Act website after the first broadcast.

    About IMPACT Melanoma

    IMPACT Melanoma, a national non-profit 501(c)(3) organization, is the nation's leading non-profit dedicated to significantly reducing melanoma in the United States and saving lives. The focus is on prevention education programs that include customized and integrated programs for communities. In addition to skin cancer prevention education and programs, the organization is committed to supporting melanoma patients and their families and advocating for and influencing urban development policies to address shade equity in America. To learn more about IMPACT Melanoma, visit https://impactmelanoma.org/.

    About The Skin Cancer Foundation

    The Skin Cancer Foundation saves and improves lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. The mission of the Foundation is to decrease the incidence of skin cancer through public and professional education and research. Since its inception in 1979, the Foundation has recommended following a complete sun protection regimen that includes seeking shade and covering up with clothing, including a wide-brimmed hat and UV-blocking sunglasses, in addition to daily sunscreen use. For more information, visit SkinCancer.org.

    About The Sun Bus

    The Sun Bus is a mobile classroom and clinic that offers a sun safety education experience that hyper-targets select audiences at varying times throughout the year. The program was launched by the Colorado Melanoma Foundation in 2019 in an effort to better address their mission of bringing free skin exams and public education to its Colorado residents. Since then, it has expanded its tour to reach 10 states, and through its combined 2021, 2022 and 2023 efforts, more than 5,456 Sun Bus visitors were screened for skin cancer by volunteer physicians. For more information and a calendar of tour locations, visit TheSunBus.org.

    About AIM at Melanoma

    Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma. By directing and funding paradigm-shifting research initiatives; educating patients, healthcare professionals and the public; and advocating for survivors and their families, AIM at Melanoma's goal is to end this disease in our lifetime while improving the lives of those it affects. AIM's work is advancing the battle against melanoma by focusing on three critical areas: innovative and collaborative research; legislation, policy and advocacy; and education. For more information, visit AimAtMelanoma.org.

    About the Melanoma Research Foundation

    The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma. Committed to the support of medical research to develop effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about the prevention, diagnosis and treatment of cutaneous melanoma and the melanoma rare subtypes. The MRF is a dedicated advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. The MRF's website is the premier source for melanoma information seekers. More information is available at Melanoma.org.

    About The Balancing Act

    The Balancing Act® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime® and find all previously aired episodes on TheBalancingAct.com.

    About Castle Biosciences

    Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

    Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

    DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

    1. The Skin Cancer Foundation; https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/; accessed 4/30/24
    2. Prevent Cancer Foundation; https://www.preventcancer.org/preventable-cancer/skin-cancer/; accessed 4/30/24

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240430859937/en/

    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Castle Biosciences with a new price target

      Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

      12/14/23 6:54:55 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Castle Biosciences with a new price target

      Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

      1/5/23 7:53:37 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Stephens & Co. initiated coverage on Castle Biosciences with a new price target

      Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

      1/7/22 5:42:05 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    SEC Filings

    See more
    • SEC Form 144 filed by Castle Biosciences Inc.

      144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      6/27/25 6:11:51 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/23/25 4:39:01 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

      SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      5/12/25 3:55:49 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

      FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. "Being recognized as a Top Workplace, ye

      7/17/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

      6/19/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. & Chief Exec. Officer Maetzold Derek J sold $458,293 worth of shares (22,576 units at $20.30), decreasing direct ownership by 7% to 69,683 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      7/1/25 4:05:26 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 5:01:17 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:19:15 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

      The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

      4/30/24 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

      SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

      5/26/21 12:42:00 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Financials

    Live finance-specific insights

    See more
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports First Quarter 2025 Results

      Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

      5/5/25 4:06:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

      FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      4/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/14/24 4:40:39 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/13/24 6:44:33 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      7/8/24 4:32:39 PM ET
      $CSTL
      Medical Specialities
      Health Care